TIGIT Inhibitors Revolutionize Immune System Control: A Comprehensive Analysis of Clinical Trials and Market Dynamics
06 sept. 2023 10h34 HE
|
Research and Markets
Dublin, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The "Anti TIGIT Antibody Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. The report...
Global Bispecific Antibodies Market Clinical Trials Antibody Sales Forecast 2028
08 déc. 2022 02h36 HE
|
KuicK Research
Delhi, Dec. 08, 2022 (GLOBE NEWSWIRE) -- "Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: Global Bispecific Antibody...
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung By Over 90% Announced by Ocean Biomedical and Aesther Healthcare (NASDAQ: AEHA)
06 sept. 2022 07h45 HE
|
Aesther Healthcare Acquisition Corp.
• Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol,...
F-star Therapeutics Appoints James Sandy as Chief Development Officer
01 mars 2022 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
20 janv. 2022 08h00 HE
|
F-star Therapeutics, Inc.
Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE...
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
07 déc. 2021 09h05 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021
01 nov. 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
20 oct. 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
12 août 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
04 août 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...